HPV Vaccination Best Practices Learning Collaborative
The AMGA Foundation is pleased to announce a call for participation for AMGA
members to participate in an HPV Vaccination Best Practices Learning
AMGA and the National HPV Vaccination
Roundtable are launching an 18-month learning collaborative to improve HPV
vaccination rates among adolescents served by medical groups and integrated
health systems. This Collaborative is based off the successful work
undertaken in AMGA’s Adult Immunization Best Practices Learning Collaborative
which resulted in 5.5 million vaccinations administered or documented over a
three year period. Funding was made possible by the Office of Infectious Disease and HIV/AIDS Policy (OIDP) via the Centers for Disease Control and Prevention under CFDA # 93.421 - Strengthening Public Health Systems and Services through National Partnerships to Improve and Protect the Nation's Health, Cooperative Agreement grant number 6 NU38OT000283-02-01.
Eight health care organizations will be recruited to participate in the
collaborative and to implement best practice interventions and strategies.
Who Should Apply
Organizations that want to be on the leading edge of adolescent population
health management have the opportunity to team with other engaged organizations
in a national forum. The objective of this program is to develop and implement
evidence-based strategies and interventions to improve HPV vaccination rates in
multi-specialty medical groups or integrated health systems with a focus on
adolescents. Collaborative members will be part of an elite group with
unique access to national leaders and organizations at in-person events and
during online webinars.
To learn more about the HPV Best Practices Learning Collaborative, download
the Call for Participation for application
guidelines. Applications are due no later than 5:30 p.m. PT on Thursday, October
What We Already Know
Fourteen million Americans acquire HPV infections each year. We do not
know what infections will clear and which infections will not. We do know
that the HPV vaccine includes strains that cause over 90% of HPV cancers,
mitigating patient risk. Approximately 92 people each day are diagnosed with an
HPV-attributable cancer. These patients and their families face the emotional
impact of a cancer diagnosis, the challenges of cancer treatment and the
possibility of death. Health systems with missions to improve health, provide
high quality care, and serve their communities have been caring for these
patients as well as managing the high financial costs that accompany cancer
care. Health systems are well positioned to expedite HPV vaccine uptake and help
eliminate HPV cancers.
To help participants succeed, AMGA’s collaborative offers a wealth of
resources and support, such as:
- Two in-person meetings: February 2020 (kick-off) January 2021 (wrap-up)
- Every other month webinars
- Online resources -- a
dedicated website for Collaborative participant material sharing and a listserv
for idea sharing and collaboration
- Consultation in the field
from AMGA, National HPV Vaccination Roundtable, and external experts
- Quality Improvement tools,
resources, and outreach
We have convened an advisory committee of industry and clinical experts that
will provide guidance to the Collaborative on the development of objectives and
educational content. The Committee includes:
Kara Elam, Ph.D., M.P.H., M.S.
ORISE Fellow in Vaccine Policy,
Office of Infectious Disease & HIV/AIDS Policy (OIDP),
U.S. Department of Health & Human Services
Melissa Gilkey, Ph.D.
Assistant Professor, Department of Health Behavior
University of North Carolina’s Gillings School of Global Health
Sarah Kobrin, Ph.D., M.P.H.
Chief of Health Systems & Research Branch
National Cancer Institute
Jason Maxwell, M.D.
Department Chair of Pediatrics and Practices
HealthPartners Como Clinic
Kristin Oliver, M.D., M.H.S.
Icahn School of
Medicine at Mount Sinai, Department of Environmental Medicine and Public Health,
Department of Pediatrics
Andrea Polkinghorn, B.S.N., RN-BC
Immunization Strategy Leader
Melinda Wharton, M.D.
Director, Immunization Services Division, NCIRD
Centers for Disease Control and Prevention
If you have questions or need further information, contact Erin
Leaver-Schmidt at firstname.lastname@example.org
or by phone at 703.838.0033 ext. 390.